In an interview to CNBC-TV18, Shashank Sinha, MD & GROUP CEO of Strides Shasun spoke about the latest happenings in his company and sector.
We wouldn’t comment on Renvela Generic partner, he said.
As of October 1, active pharmaceutical ingredient (API) is going to be a different business. In Strides, we are going to keep our captive APIs and the third party API supply is carved out into a different business. I am not at liberty to talk about their business portfolio. It is a significant product. It is going to be spun off into a separate company which is going to list separately, he added.
Strides will be a vertically integrated formulation company, said Sinha.
One approval pending from the National Company Law Tribunal (NCLT) for the demerger, he further mentioned.
On Lovaza generic, he said the market size is USD 200-300 million, it is a dynamic market.For full interview, watch accompanying video...